Laquinimod is an experimental
immunomodulator
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as ''activation immunotherapies,'' while immunotherap ...
developed by Active Biotech and
Teva
Teva is the Hebrew word for nature ( he, טבע, "nature").
Teva may refer to:
Companies
* Teva Footwear, American footwear manufacturer
* Teva Naot, Israeli footwear manufacturer
* Teva Pharmaceuticals, Israeli multinational pharmaceutical com ...
. It is being investigated as an oral treatment for
multiple sclerosis (MS).
Laquinimod is the successor of Active Biotech's failed experimental immunomodulator
linomide.
The compound has been investigated in two Phase II trials using successive
magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.
However, the response to a given dose was discrepant between both studies.
Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses in MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.
On May 7, 2013 laquinimod was approved by the Russian
Ministry of Health Ministry of Health may refer to:
Note: Italics indicate now-defunct ministries.
* Ministry of Health (Argentina)
* Ministry of Health (Armenia)
* Australia:
** Ministry of Health (New South Wales)
* Ministry of Health (The Bahamas)
* Ministry of ...
(the
FDA analog) as a treatment for relapsing-remitting multiple sclerosis (RRMS) under the brand name Nerventra.
See also
*
Management of multiple sclerosis
References
External links
Entries in NIH Study Registry
Immunosuppressants
{{antineoplastic-drug-stub